Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nuvectis Pharma, Inc. - Common Stock (NQ: NVCT ) 5.248 +0.228 (+4.55%) Streaming Delayed Price Updated: 12:10 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Nuvectis Pharma, Inc. - Common Stock < Previous 1 2 Next > Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium December 10, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort November 14, 2024 Via AB Newswire Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer November 14, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update October 28, 2024 From PESG Research Via Business Wire Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics October 23, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference October 07, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch September 16, 2024 From PESG Research Via Business Wire Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 05, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT) August 15, 2024 Via AB Newswire Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market July 18, 2024 Via AB Newswire Precision Medicine M&A is Transforming the Future of the Biotech Industry June 17, 2024 Via AB Newswire Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference May 16, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines April 08, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting March 19, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma to Present at the 36th Annual Roth Conference March 15, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer March 14, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences February 09, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Participation at Upcoming Investor Conferences February 09, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma December 18, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer October 24, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation September 25, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900 September 21, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial September 12, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900 September 06, 2023 Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Participation at Upcoming Investor Conferences September 01, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma August 17, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes June 20, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Announces FDA Clearance of NXP900 IND May 15, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference April 27, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire < Previous 1 2 Next > Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
